Kiniksa Pharmaceuticals News

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaApr 24 13:38 ET

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects

TipRanksApr 24 05:44 ET

Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution

TipRanksApr 23 11:05 ET

Kiniksa Pharmaceuticals (KNSA) Receives a Buy From Goldman Sachs

TipRanksApr 2 14:55 ET

Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)

TipRanksFeb 28 12:00 ET

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)

TipRanksJan 5 04:32 ET

Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating

TipRanksJan 4 15:15 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaJan 2 10:59 ET

Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and UnitedHealth (UNH)

TipRanksJan 2 08:20 ET

Promising Growth and Strategic Investments Bolster Buy Rating for Kiniksa Pharmaceuticals

TipRanksNov 1, 2023 05:34 ET

J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

TipRanksAug 12, 2023 08:15 ET

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32

BenzingaJul 26, 2023 09:39 ET

Kiniksa Pharmaceuticals Analyst Ratings

BenzingaJul 26, 2023 09:37 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tarsus Pharmaceuticals (TARS), Kiniksa Pharmaceuticals (KNSA) and Danaher (DHR)

TipRanksJul 26, 2023 06:41 ET

Goldman Sachs Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)

TipRanksJul 25, 2023 15:05 ET

Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating

MT NewswiresJul 25, 2023 13:02 ET

Goldman Sachs Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

TipRanksMay 2, 2023 13:41 ET

Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating

MT NewswiresMay 2, 2023 12:11 ET

JPMorgan Adjusts Kiniksa Pharmaceuticals' Price Target to $20 From $19, Keeps Overweight Rating

MT NewswiresMar 9, 2023 11:01 ET

Wedbush Lowers Kiniksa Pharmaceuticals' Price Target to $20 From $26, Adjusts Commercial Ramp Assumptions for Arcalyst; Keeps Outperform Rating

MT NewswiresMar 1, 2023 07:28 ET